Advertisement

Photobiomodulation-induced analgesia in experimental temporomandibular disorder involves central inhibition of fractalkine

  • João Ignácio Ferrara-Jr
  • Everton Tiago de Souza
  • Adriano Cardozo Franciosi
  • Elaine Flamia Toniolo
  • Camila Squarzoni DaleEmail author
Original Article
  • 31 Downloads

Abstract

Temporomandibular disorder (TMD) is a collective term that encompasses a set of clinical problems that affect the masticatory muscles, the temporomandibular joint, and associated structures. Despite their high clinical prevalence, the mechanisms of chronic craniofacial muscle pain are not yet well understood. Treatments for TMD pain relief and control should be minimally invasive, reversible, and conservative. Photobiomodulation (PBM) is a promising option once it is known to inhibit inflammatory response and to relief painful symptoms. Herein, the effects of PBM (660 nm, 30 mW, 16 J/cm2, 0.2 cm2, 15 s in a continuous frequency) on the pain sensitivity of rats submitted to an experimental model of TMD induced by CFA was evaluated. Experimental TMD was induced in rats by the injection of complete Freund’s adjuvant (CFA) injection into the masseter muscle. Nociceptive behavior was evaluated by electronic von Frey before CFA and after 1 h, 3 h, 6 h, and 24 h and 7, 14, and 21 days after PBM treatment. Inflammatory infiltrate was evaluated by histology of the masseter muscle and fractalkine expression was evaluated by immunohistochemistry of the trigeminal ganglia. PBM reversed the mechanical hypersensitivity of the animals by inhibiting the local inflammatory response, observed by the decrease of the inflammatory infiltrate in the masseter muscle of rats and by a central inhibition of fractalkine observed in the trigeminal ganglion. These data provide new insights into the mechanisms involved in the effects of photobiomodulation therapy emphasizing its therapeutic potential in the treatment of TMD.

Keywords

Photobiomodulation Orofacial pain Microglia Fractalkine Inflammation 

Notes

Acknowledgements

CSD thanks the National Council for Scientific and Technological Development (CNPq, Brazil) for the productivity fellowship. ACF thanks FAPESP for the PhD grant (FAPESP 2012/03865-0). ETS and EFT thank for CNPq grants.

Funding

This work was supported by FAPESP (grant no. 2015/17136-8). The authors declare no conflicts of interest.

Compliance with ethical standards

Throughout the experiments, animals were managed using the principles and guidelines for the care of laboratory animals in studies involving pain and were approved by the Ethics Committee on the Use of Animals at University of São Paulo (CEUA, protocol no. 020/2014).

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Köhler AA, Hugoson A, Magnusson T (2013) Clinical signs indicative of temporomandibular disorders in adults: time trends and associated factors. Swed Dent J 37:1–11Google Scholar
  2. 2.
    Macfarlane TV, Glenny AM, Worthington HV (2001) Systematic review of population-based epidemiological studies of oro-facial pain. J Dent 29:451–457CrossRefGoogle Scholar
  3. 3.
    de Siqueira SR, Vilela TT, Florindo AA (2015) Prevalence of headache and orofacial pain in adults and elders in a Brazilian community: an epidemiological study. Gerodontology 32:123–131CrossRefGoogle Scholar
  4. 4.
    Gonçalves DA, Dal Fabbro AL, Campos JADB, Bigal ME, Speciali JG (2010) Symptoms of temporomandibular disorders in the population: an epidemiological study. J Orofac Pain 24:270–278Google Scholar
  5. 5.
    Machado LP, Nery Cde G, Leles CR, Nery MB, Okeson JP (2009) The prevalence of clinical diagnostic groups in patients with temporomandibular disorders. Cranio 27(3):194–199CrossRefGoogle Scholar
  6. 6.
    Ambalavanar R, Yallampalli C, Yallampalli U, Dessem D (2007) Injection of adjuvant but not acidic saline into craniofacial muscle evokes nociceptive behaviors and neuropeptide expression. Neuroscience 149(3):650–659CrossRefGoogle Scholar
  7. 7.
    Barbe MF, Barr AE (2006) Inflammation and the pathophysiology of work-related musculoskeletal disorders. Brain Behav Immun 20(5):423–429CrossRefGoogle Scholar
  8. 8.
    Carroll JD, Milward MR, Cooper PR, Hadis H, Palin WM (2014) Developments in low level light therapy (LLLT) for dentistry. Dent Mater 30(5):465–475CrossRefGoogle Scholar
  9. 9.
    Herpich CM, Leal-Junior ECP, Amaral AP, Tosato JP, Glória IPS, Garcia MBS, Barbosa BRB, El Hage Y, Arruda EEC, Gomes CAFP, Rodrigues MS, de Sousa DFM, Carvalho PTC, Bussadori SK, Gonzalez TO, Politti F, Biasotto-Gonzalez DA (2015) Analysis of laser therapy and assessment methods in the rehabilitation of temporomandibular disorder: a systematic review of the literature. J Phys Ther Sci 27(1):295–301CrossRefGoogle Scholar
  10. 10.
    Melis M, Di Giosia M, Zawawi KH (2012) Low level laser therapy for the treatment of temporomandibular disorders: a systematic review of the literature. Cranio 30(4):304–312CrossRefGoogle Scholar
  11. 11.
    Carrasco TG, Mazzetto MO, Mazzetto RG, Mestriner W (2008) Low intensity laser therapy in temporomandibular disorder: a phase II double-blind study. Cranio 26:274–281CrossRefGoogle Scholar
  12. 12.
    Mazzetto MO, Carrasco TG, Bidinelo EF, Pizzo RCA, Mazzetto RG (2007) Low intensity laser application in temporomandibular disorders: a phase I double-blind study. Cranio 25(3):186–192CrossRefGoogle Scholar
  13. 13.
    Melchior M de O, Venezian GC, Machado BC, Borges RF, Mazzetto MO (2013) Does low intensity laser therapy reduce pain and change orofacial myofunctional conditions? Cranio 31(2):133–139CrossRefGoogle Scholar
  14. 14.
    Venezian GC, Silva ARM, Mazzetto RG, Mazzetto MO (2010) Low level laser effects on pain to palpation and electromyographic activity in TMD patients: a double-blind, randomized, placebo-controlled study. Cranio 28:84–91CrossRefGoogle Scholar
  15. 15.
    Núñez SC, Garcez AS, Suzuki SS, Ribeiro MS (2006) Management of mouth opening in patients with temporomandibular disorders through low-level laser therapy and transcutaneous electrical neural stimulation. Photomed Laser Surg 24:45–49CrossRefGoogle Scholar
  16. 16.
    Çetiner S, Kahraman SA, Yücetas S (2006) Evaluation of low-level laser therapy in the treatment of temporomandibular disorders. Photomed Laser Surg 24:637–641CrossRefGoogle Scholar
  17. 17.
    da Silva MAMR, Botelho AL, Turim CV, da Silva AMR (2012) Low level laser therapy as an adjunctive technique in the management of temporomandibular disorders. Cranio 30:264–271CrossRefGoogle Scholar
  18. 18.
    Cao Y, Li K, Fu KY, Xie QF, Chiang CY, Sessle BJ (2013) Central sensitization and MAPKs are involved in occlusal interference-induced facial pain in rats. J Pain 14:793–807CrossRefGoogle Scholar
  19. 19.
    Chiang CY, Dostrovsky DO, Iwata K, Sessle BJ (2011) Role of glia in orofacial pain. Neuroscientist 17:303–320CrossRefGoogle Scholar
  20. 20.
    Deguchi T, Adachi R, Kamioka H, Kim DG, Fields HW, Takano-Yamamoto T, Ichikawa H, Yamashiro T (2016) Effect of minocycline on induced glial activation by experimental tooth movement. Am J Orthod Dentofac Orthop 149:881–888CrossRefGoogle Scholar
  21. 21.
    Kiyomoto M, Shinoda M, Honda K, Nakaya Y, Dezawa K, Katagiri A, Kamakura S, Inoue T, Iwata K (2015) p38 phosphorylation in medullary microglia mediates ectopic orofacial inflammatory pain in rats. Mol Pain 11:48CrossRefGoogle Scholar
  22. 22.
    Lee S, Zhao YQ, Ribeiro-da-Silva A, Zhang J (2010) Distinctive response of CNS glial cells in oro-facial pain associated with injury, infection and inflammation. Mol Pain 6:79Google Scholar
  23. 23.
    Sugiyo S, Takemura M, Dubner R, Ren K (2005) Trigeminal transition zone/rostral ventromedial medulla connections and facilitation of orofacial hyperalgesia after masseter inflammation in rats. J Comp Neurol 493:510–523CrossRefGoogle Scholar
  24. 24.
    Clark AK, Staniland AA, Malcangio M (2011) Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol 12:1707–1714CrossRefGoogle Scholar
  25. 25.
    Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU (2002) Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 69:418–426CrossRefGoogle Scholar
  26. 26.
    Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37:314–327CrossRefGoogle Scholar
  27. 27.
    Jones BA, Beamer M, Ahmed S (2010) Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol Interv 10:263–270CrossRefGoogle Scholar
  28. 28.
    Milligan ED, Sloane EM, Watkins LR (2008) Glia in pathological pain: a role for fractalkine. J Neuroimmunol 198:113–120CrossRefGoogle Scholar
  29. 29.
    Souza GR, Talbot J, Lotufo CM, Cunha FQ, Cunha TM, Ferreira SH (2013) Fractalkine mediates inflammatory pain through activation of satellite glial cells. PNAS 110:11193–11198CrossRefGoogle Scholar
  30. 30.
    Kiyomoto M, Shinoda M, Okada-Ogawa A, Noma N, Shibuta K, Tsuboi Y, Sessle BJ, Imamura Y, Iwata K (2013) Fractalkine signaling in microglia contributes to ectopic orofacial pain following trapezius muscle inflammation. J Neurosci 33:7667–7680CrossRefGoogle Scholar
  31. 31.
    Cairns BE, O’Brien M, Dong XD, Gazerani P (2017) Elevated fractalkine (CX3CL1) levels in the trigeminal ganglion mechanically sensitize temporalis muscle nociceptors. Mol Neurobiol 54:3695–3706CrossRefGoogle Scholar
  32. 32.
    Denadai-Souza A, Camargo LL, Ribela MTCP, Keeble JE, Costa SKP, Muscará MN (2009) Participation of peripheral tachykinin NK1 receptors in the carrageenan-induced inflammation of the rat temporomandibular joint. Eur J Pain 13:812–819CrossRefGoogle Scholar
  33. 33.
    Capra NF, Ro JY (2004) Human and animal experimental models of acute and chronic muscle pain: intramuscular algesic injection. Pain 110:3–7CrossRefGoogle Scholar
  34. 34.
    Imbe H, Iwata K, Zhou QQ, Zou S, Dubner R, Ren K (2001) Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation. Implications for persistent temporomandibular pain. Cells Tissues Organs 169:238–247CrossRefGoogle Scholar
  35. 35.
    Okumura M, Iwata K, Yasuda K, Inoue K, Shinoda M, Honda K, Shibuta K, Yasuda M, Kondo E (2010) Alternation of gene expression in trigeminal ganglion neurons following complete Freund’s adjuvant or capsaicin injection into the rat face. J Mol Neurosci 42:200–209CrossRefGoogle Scholar
  36. 36.
    Ahrari F, Madani AS, Ghafouri ZS, Tunér J (2014) The efficacy of low-level laser therapy for the treatment of myogenous temporomandibular joint disorder. Lasers Med Sci 29:551–557CrossRefGoogle Scholar
  37. 37.
    Moraes Maia ML, Ribeiro MA, Maia LG, Stuginski-Barbosa J, Costa YM, Porporatti AL, Conti PC, Bonjardim LR (2014) Evaluation of low-level laser therapy effectiveness on the pain and masticatory performance of patients with myofascial pain. Lasers Med Sci 29:29–35CrossRefGoogle Scholar
  38. 38.
    Rodrigues JH, Marques MM, Biasotto-Gonzalez DA, Moreira MS, Bussadori SK, Mesquita-Ferrari RA, Martins MD (2015) Evaluation of pain, jaw movements, and psychosocial factors in elderly individuals with temporomandibular disorder under laser phototherapy. Lasers Med Sci 30:953–959CrossRefGoogle Scholar
  39. 39.
    Salmos-Brito JA, Menezes RF, Teixeira CE, Gonzaga RK, Rodrigues BH, Braz R, Bessa-Nogueira RV, Gerbi ME (2013) Evaluation of low-level laser therapy in patients with acute and chronic temporomandibular disorders. Lasers Med Sci 28:57–64CrossRefGoogle Scholar
  40. 40.
    Shirani AM, Gutknecht N, Taghizadeh M, Mir M (2009) Low-level laser therapy and myofacial pain dysfunction syndrome: a randomized controlled clinical trial. Lasers Med Sci 24:715–720CrossRefGoogle Scholar
  41. 41.
    Peplow PV, Chung TY, Baxter GD (2012) Laser photostimulation (660 nm) of wound healing in diabetic mice is not brought about by ameliorating diabetes. Lasers Surg Med 44(1):26–29CrossRefGoogle Scholar
  42. 42.
    Ayuk SM, Houreld NN, Abrahamse H (2018) Effect of 660 nm visible red light on cell proliferation and viability in diabetic models in vitro under stressed conditions. Lasers Med Sci 33:1085–1093CrossRefGoogle Scholar
  43. 43.
    Houreld NN, Ayuk SM, Abrahamse H (2018) Cell adhesion molecules are mediated by photobiomodulation at 660 nm in diabetic wounded fibroblast cells. Cells 7:30CrossRefGoogle Scholar
  44. 44.
    Oliveira ME, Santos FM, Bonifácio RP, Freitas MF, Martins DO, Chacur M (2017) Low level laser therapy alters satellite glial cell expression and reverses nociceptive behavior in rats with neuropathic pain. Photochem Photobiol Sci 16:547–554CrossRefGoogle Scholar
  45. 45.
    Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR (2004) A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24:7353–7365CrossRefGoogle Scholar
  46. 46.
    Milligan E, Zapata V, Schoeniger D, Chacur M, Green P, Poole S, Martin D, Maier SF, Watkins LR (2005) An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci 22:2775–2782CrossRefGoogle Scholar
  47. 47.
    Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O’Connor KA, Verge GM, Chapman G, Green P, Foster AC, Naeve GS, Maier SF, Watkins LR (2004) Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20:2294–2302CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Laboratory of Neuromodulation of Experimental Pain, Department of Anatomy, Insitute of Biomedical SciencesUniversity of São PauloSao PauloBrazil
  2. 2.University City of São PauloSao PauloBrazil

Personalised recommendations